KTRA vs. CING, KZIA, CPHI, SNPX, NEXI, DRUG, TFFP, RNAZ, ARTL, and PTIX
Should you be buying Kintara Therapeutics stock or one of its competitors? The main competitors of Kintara Therapeutics include Cingulate (CING), Kazia Therapeutics (KZIA), China Pharma (CPHI), Synaptogenix (SNPX), NexImmune (NEXI), Bright Minds Biosciences (DRUG), TFF Pharmaceuticals (TFFP), TransCode Therapeutics (RNAZ), Artelo Biosciences (ARTL), and Protagenic Therapeutics (PTIX). These companies are all part of the "pharmaceutical preparations" industry.
Cingulate (NASDAQ:CING) and Kintara Therapeutics (NASDAQ:KTRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership, community ranking and dividends.
Cingulate has a beta of -0.87, indicating that its share price is 187% less volatile than the S&P 500. Comparatively, Kintara Therapeutics has a beta of 0.42, indicating that its share price is 58% less volatile than the S&P 500.
41.3% of Cingulate shares are held by institutional investors. Comparatively, 0.6% of Kintara Therapeutics shares are held by institutional investors. 21.8% of Cingulate shares are held by company insiders. Comparatively, 4.8% of Kintara Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Cingulate and Cingulate both had 2 articles in the media. Cingulate's average media sentiment score of 0.46 beat Kintara Therapeutics' score of -0.43 indicating that Kintara Therapeutics is being referred to more favorably in the news media.
Cingulate currently has a consensus price target of $8.00, indicating a potential upside of 995.89%. Given Kintara Therapeutics' higher probable upside, analysts clearly believe Cingulate is more favorable than Kintara Therapeutics.
Kintara Therapeutics received 10 more outperform votes than Cingulate when rated by MarketBeat users. Likewise, 88.89% of users gave Kintara Therapeutics an outperform vote while only 66.67% of users gave Cingulate an outperform vote.
Summary
Kintara Therapeutics beats Cingulate on 7 of the 10 factors compared between the two stocks.
Get Kintara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for KTRA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding KTRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Kintara Therapeutics Competitors List
Related Companies and Tools
